BHU gets patent on tri-target antiviral activity against SARS CoV2

NEW DELHI: The Banaras Hindu University (BHU) has received a German patent for its work on the identification of tri-target antiviral activity against the SARS CoV2 virus.

Parimal Das led the team along with researchers from the Centre for Genetic Disorders and the Department of Zoology at the Institute of Science. They have developed a system that targets three crucial proteins of the virus, paving the way for COVID-19 treatment.

ALSO READ| BHU scientists secure permission for German patent for system to inhibit growth of covid virus

Das said, "We are thrilled to have been granted a second international patent for our research on Sominone. This is a significant milestone in our ongoing efforts to combat the SARS CoV2 virus.”

BHU research

The team focused on Sominone, a novel antiviral molecule derived from Aswagandha, which has demonstrated an impressive 96 percent inhibition rate against the SARS CoV2 virus. The researchers worked to uncover the properties of Sominone. This latest achievement will help in antiviral research, specifically in developing effective treatments for COVID-19.

BHU German Patent research team(Image source: Official website)

“We hope that our findings will contribute to the development of novel antiviral therapies and ultimately help in the fight against the COVID-19 pandemic.", said Das.

The recently granted German patent shows the team's commitment to the field of antiviral research. This international recognition acknowledges the innovative approach and potential impact of their research, which holds promise for the development of novel antiviral therapies.

ALSO READ| BHU to launch scholarship for economically weak MBBS students

BHU's Centre for Genetic Disorders and Department of Zoology have long been recognized for their research in the fields of molecular biology and genetics. This latest achievement highlights their commitment to scientific excellence and their pursuit of innovative solutions to global health challenges.